Variations of the phosphorylation of 1-beta-D-arabinofuranosylcytosine (ARA-C) in human myeloid leukemic cells related to the cell cycle

Leukemia Research
G VierwindenC Haanen

Abstract

Bone marrow cells of five patients with acute myeloid leukemia were fractionated by means of counterflow centrifugation (elutriation). The different fractions were enriched with cells belonging to subsequent stages of the cell cycle. Cytokinetic evaluation of these cell fractions was performed by [3H]thymidine autoradiography, [3H]thymidine incorporation and DNA/RNA-flow cytometry. Phosphorylation of cytosine arabinoside (ara-C, 1-beta-D-arabinofuranosylcytosine) in the different fractions was measured by incubation of the cells for 30 min with 1.07 microM [3H]ara-C. Phosphorylation of ara-C in the whole bone marrow samples ranged from 5.9 to 33.2 pmol/10(6) cells. In the fractions containing only G1-phase cells, phosphorylation ranged from 1.2 to 19.5 pmol/10(6) cells. The phosphorylation seems to increase before DNA synthesis starts. Maximal activities were found in the fractions enriched with cells in late G1- or S-phase of the cell cycle. In these fractions the ara-C phosphorylating activity was 1.5-8 times higher compared to the fractions with the lowest activity. One may therefore assume that not only S-phase cells are killed by ara-C, but that G1-phase cells which can phosphorylate ara-C, may also be doomed when they ent...Continue Reading

References

Jan 1, 1977·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·F TraganosM R Melamed
May 24, 1979·The New England Journal of Medicine·R P Gale
Aug 1, 1978·Computers and Biomedical Research, an International Journal·D A JohnstonB Barlogie
Jul 1, 1976·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J F SmythC L Leese
Nov 1, 1976·Biophysical Journal·S I Rubinow, J L Lebowitz
Nov 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·Z DarzynkiewiczM R Melamed
Jul 1, 1980·British Journal of Haematology·A L Harris, D G Grahame-Smith
Jan 1, 1981·Leukemia Research·A M Drenthe-SchonkC Haanen
Jan 1, 1981·Journal of Immunological Methods·P H De MulderC Haanen

❮ Previous
Next ❯

Citations

Jan 1, 1992·Cancer Chemotherapy and Pharmacology·V Gandhi, W Plunkett
Feb 1, 1985·The Journal of Clinical Investigation·J S WileyL R Finch
Feb 1, 1992·Japanese Journal of Cancer Research : Gann·M Tanaka
Jul 1, 1985·Indian Journal of Pediatrics·A M Galazka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.